FDA – Page 77 – Pharma.Tips

PV system audit finding during benefit–risk assessment – how to strengthen benefit–risk documentation

Addressing Audit Findings in Pharmacovigilance Systems During Benefit-Risk Assessments Pharmaceutical companies are increasingly under pressure to ensure that their pharmacovigilance (PV) systems align with regulatory expectations, especially during benefit-risk assessments.…

Packaging compatibility risk during scale-up – how to prevent recall triggers

Mitigating Packaging Compatibility Risks During Scale-Up to Prevent Recalls In pharmaceutical manufacturing, scale-up processes can expose weaknesses in packaging compatibility that might not have been apparent during smaller production runs.…

Case processing backlog during inspection – inspection questioning scenarios

Understanding and Addressing Case Processing Backlogs During Inspections In the highly regulated pharmaceutical environment, inspections can reveal unexpected challenges, including case processing backlogs that may arise during operations. These backlogs…

Extractables and leachables concern during scale-up – CAPA and control strategy

Addressing Extractables and Leachables Issues During Scale-Up: A Comprehensive Investigation Approach During the scale-up of pharmaceutical products, concerns related to extractables and leachables (E&L) can significantly impact product quality and…

Risk management plan gaps during inspection – preventing repeat PV findings

Addressing Gaps in Risk Management Plans During Inspections to Prevent Recurrent Findings In the highly regulated pharmaceutical environment, maintaining robust risk management plans is critical, especially during inspections conducted by…

Container closure integrity risk during development – how to prevent recall triggers

Assessing and Mitigating Container Closure Integrity Risks During Development In the pharmaceutical industry, ensuring container closure integrity (CCI) is paramount during the development phase to prevent potential product recalls and…

Safety signal escalation delay during post-marketing surveillance – inspection questioning scenarios

Addressing Delays in Safety Signal Escalation During Post-Marketing Surveillance Delays in safety signal escalation during post-marketing surveillance can pose significant regulatory challenges for pharmaceutical companies. Such delays not only hinder…

Artwork change error during market launch – documentation gaps regulators question

“`html Investigating Artwork Change Errors During Market Launch: Documentation Gaps That Raise Regulatory Questions In the pharmaceutical industry, the accuracy of product artwork is a critical aspect of compliance and…

PV system audit finding during signal review – regulatory enforcement risk and mitigation

Addressing Regulatory Risks from PV System Audits During Signal Reviews Pharmaceutical vigilance (PV) systems play a critical role in ensuring safety and efficacy monitoring of marketed products. An audit finding…

Stability impact underestimated during market launch – CAPA and control strategy

Underestimating Stability Impact During Market Launch: A Comprehensive Investigation In the fast-paced world of pharmaceutical manufacturing, ensuring product stability during the market launch is crucial to maintaining quality and compliance.…

Risk management plan gaps during post-marketing surveillance – preventing repeat PV findings

Addressing Gaps in Risk Management Plans During Post-Marketing Surveillance Pharmaceutical companies often face challenges with their risk management plans (RMPs), particularly during post-marketing surveillance. Gaps in RMPs can lead to…

Container closure integrity risk during market launch – documentation gaps regulators question

Assessing Risks to Container Closure Integrity During Market Launch In the pharmaceutical manufacturing sphere, ensuring container closure integrity (CCI) is paramount, especially during the critical phase of market launch. Recent…